FI20030393A0 - Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi - Google Patents
Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksiInfo
- Publication number
- FI20030393A0 FI20030393A0 FI20030393A FI20030393A FI20030393A0 FI 20030393 A0 FI20030393 A0 FI 20030393A0 FI 20030393 A FI20030393 A FI 20030393A FI 20030393 A FI20030393 A FI 20030393A FI 20030393 A0 FI20030393 A0 FI 20030393A0
- Authority
- FI
- Finland
- Prior art keywords
- predicting
- treat
- compounds
- course
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20030393A FI20030393A7 (fi) | 2003-03-14 | 2003-03-14 | Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi |
| EP04720024A EP1603571A2 (en) | 2003-03-14 | 2004-03-12 | Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof |
| PCT/FI2004/000145 WO2004080271A2 (en) | 2003-03-14 | 2004-03-12 | Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof |
| US11/225,095 US20060057628A1 (en) | 2003-03-14 | 2005-09-14 | Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20030393A FI20030393A7 (fi) | 2003-03-14 | 2003-03-14 | Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI20030393A0 true FI20030393A0 (fi) | 2003-03-14 |
| FI20030393L FI20030393L (fi) | 2004-09-15 |
| FI20030393A7 FI20030393A7 (fi) | 2004-09-15 |
Family
ID=8565817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI20030393A FI20030393A7 (fi) | 2003-03-14 | 2003-03-14 | Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20060057628A1 (fi) |
| EP (1) | EP1603571A2 (fi) |
| FI (1) | FI20030393A7 (fi) |
| WO (1) | WO2004080271A2 (fi) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7754709B2 (en) | 2003-06-10 | 2010-07-13 | Solvay Pharmaceuticals Bv | Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds |
| US7524853B2 (en) | 2003-06-10 | 2009-04-28 | Solvay Pharmaceuticals B.V. | Compounds and their use in therapy |
| US8088758B2 (en) | 2003-11-12 | 2012-01-03 | Abbott Products Gmbh | 17β-hydroxysteroid dehydrogenase type I inhibitors |
| RU2409581C2 (ru) * | 2004-12-13 | 2011-01-20 | Зольвай Фармасьютиклз Гмбх | НОВЫЕ ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ТИОФЕНПИРИМИДИНОНА В КАЧЕСТВЕ ИНГИБИТОРОВ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ |
| ES2327240T3 (es) * | 2004-12-13 | 2009-10-27 | Solvay Pharmaceuticals Gmbh | Nuevos derivados sustituidos de tiofempirimidinona en calidad de inhibidores de 17beta-hidroxiesteroide deshidrogenasa. |
| US8030298B2 (en) | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
| US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| CN101884706B (zh) * | 2010-07-01 | 2014-05-28 | 广州市花城制药厂 | 一种祛痰止咳颗粒的检测方法 |
-
2003
- 2003-03-14 FI FI20030393A patent/FI20030393A7/fi not_active Application Discontinuation
-
2004
- 2004-03-12 EP EP04720024A patent/EP1603571A2/en not_active Withdrawn
- 2004-03-12 WO PCT/FI2004/000145 patent/WO2004080271A2/en not_active Ceased
-
2005
- 2005-09-14 US US11/225,095 patent/US20060057628A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| FI20030393L (fi) | 2004-09-15 |
| FI20030393A7 (fi) | 2004-09-15 |
| WO2004080271A2 (en) | 2004-09-23 |
| WO2004080271A3 (en) | 2004-11-04 |
| EP1603571A2 (en) | 2005-12-14 |
| US20060057628A1 (en) | 2006-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1667680A4 (en) | COMBINATION PROCEDURE FOR THE TREATMENT OF CANCER | |
| EP1575580A4 (en) | METHOD FOR TREATING CARCINOMA | |
| IL258880A (en) | Diarylhydantoin compounds | |
| EP1696877A4 (en) | PROCESS FOR PAIN TREATMENT | |
| IS8125A (is) | Kínasólínafleiður til að meðhöndla krabbamein | |
| EP1663259A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER | |
| EP1814909A4 (en) | USE OF AIMP2DX2 FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
| CY1109741T1 (el) | Sns-595 και μεθοδοι χρησης αυτου | |
| EP1967209A4 (en) | THERAPEUTIC AGENT AGAINST PROSTATE CANCER | |
| DK1706112T3 (da) | Fremgangsmåder til at behandle en inflammatorisk-beslægtet sygdom | |
| MA28802B1 (fr) | Utilisations therapeutiques d'inhibiteurs de rtp801 | |
| IL180601A0 (en) | Methods and compositions for the detection of ovarian cancer | |
| HUE048404T2 (hu) | Claudin-18 elleni monoklonális antitestek rák kezelésére | |
| ATE527241T1 (de) | Pyridiazinonderivate zur behandlung von tumoren | |
| EP1677794A4 (en) | METHODS OF TREATING DISORDERS | |
| NL1025873A1 (nl) | Doseringsvormen en wijzen van behandeling met vegfr-remmers. | |
| FI20021807L (fi) | Menetelmä akryyliamidin muodostumisen estämiseksi tai vähentämiseksi elintarvikkeissa | |
| FI20030771A7 (fi) | Menetelmä toksisten syanobakteerien määrittämiseksi | |
| DE602004032525D1 (de) | Rstellungsverfahren dafür | |
| EP1594433A4 (en) | SENSITIZING A CANCER THERAPY | |
| FI20030393A0 (fi) | Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi | |
| DK1611890T3 (da) | Fremgangsmåde til evaluering og behandling af cancer | |
| EP1902068A4 (en) | EGFR INHIBITORS AS PROMOTERS OF NEURITE GENERATION | |
| DE602004026773D1 (de) | Verfahrensherstellung von ethern | |
| EP1789064A4 (en) | ENHANCED ANTICANCER TREATMENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application lapsed |